Indeed, a reverse phase phosphoprotein array (RPPA)-based profiling of key receptor tyrosine kinases (RTKs) and their nodal proteins in the tumour biopsies revealed a heterogeneity in the baseline activation levels of these receptors and downstream signals (Fig. 3a and Supplementary Fig. 5a,b). The gene discussed is NTRK1; the disease is neoplasm.